MEDX HOLDINGS, INC.

A WYOMING CORPORATION

COMPANY INFORMATION AND DISCLOSURE STATEMENT
Pursuant to Pink Sheet Basic Disclosure Guidelines

All information in this Information and Disclosure Statement has been compiled to fulfill the disclosure requirements of the OTC Markets regarding Pink Sheet Basic Disclosure Guidelines.

No Dealer, salesman or any other person has been authorized to give any information, or to make any representations, not contained herein in connection with the issuer. Such information or representations if made should not be relied upon as having been authorized by the issuer and;

Delivery of this information file does not at any time imply that the information contained herein is correct as of any time subsequent to the date first written.

The undersigned hereby certifies that the information herein is true and correct to the best of their knowledge and belief.

Date: February 18, 2016

MedX Holdings, Inc.

/s/ Kathleen Roberton
Name: Kathleen Roberton
Position: Director and CEO
Email: info@medxholdings.com
Phone: 877-337-3756

MEDX HOLDINGS, INC.
DISCLOSURE STATEMENT

December 31, 2015

Item 1: The exact name of the issuer and the address of its executive offices:

The exact name of the issuer is: MedX Holdings, Inc.
August 12, 2015 – Cantor Group, Inc.
November 13, 2006 - Disaboom, Inc.
September 5, 2006 - Disaboo, Inc.

Item 2: The Address of its principal executive offices:

1621 Central Avenue
Cheyenne Wyoming 82001

Phone: 877-225-0243
Fax: 954-337-3756
Website: www.medxholdings.com

Item 3: Security Information

Security Symbol:	MEDH
CUSIP Number:	58403T 107
Common Stock:	25,569,016 Issued and Outstanding as of 12/31/2015
Par Value:	$0.001 on both Common and Blank Check Preferred

Authorized Share Structure:

As of:	12/31/2014	Par Value	12/31,2015	Par Value
Total Authorized Common	100,000,000	$0.0001	100,000,000	$0.001
Total Authorized Preferred				
Series A Preferred	10,000,000	$0.0001		
Blank Check Preferred			100,000,000	$0.001
Shareholders				

Transfer Agent:

Daniel Bell, Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, Colorado 80209
Phone: 303-282-4800

CST currently meets all requirements and is registered under the Securities Exchange Act.

Restrictions on transfer of Securities or suspensions by the SEC in the past 12 months:

None

Stock Split:

On September 9, 2015 a 250 for 1 reverse stock split was approved. All fractional shares were rounded up to 1 share.

Increase in Preferred Stock:

On 12/28/2015 the Company increased the Preferred Shares Authorized (Blank Check) to 100,000,000, par value $0.001.

Item 4: Issuance History

No significant issuances or changes have taken place in the past 2 years not yet disclosed.

Item 5: Financial Statements

- Balance Statement
- Profit and Loss Statement
- Statement of Cash Flows
- Financial Notes

MEDX HOLDINGS, INC.

(A Development Stage Company)

Balance Sheet

As of December 31, 2015

	Total	
	As of Dec 31, 2015	As of Dec 31, 2014
ASSETS		
Current Assets		
Bank Accounts		
Checking	1,709.25	
Total Bank Accounts	$ 1,709.25	$ 0.00
Total Current Assets	$ 1,709.25	$ 0.00
Other Assets		
CAPITAL ASSETS	146,000.00	146,000.00
Capitalized Re-Organization Costs	13,000.00	
Total Other Assets	$ 159,000.00	$ 146,000.00
TOTAL ASSETS	$ 160,709.25	$ 146,000.00
LIABILITIES AND EQUITY		
Liabilities		
Current Liabilities		
Other Current Liabilities		
Accrued Liabilities	0.00	16,000.00
Due to related party	27,000.00	
Total Other Current Liabilities	$ 27,000.00	$ 16,000.00
Total Current Liabilities	$ 27,000.00	$ 16,000.00
Total Liabilities	$ 27,000.00	$ 16,000.00
Equity		
Common Stock	4,221.00	4,221.00
Paid-In Capital or Surplus	717,239.00	717,239.00
Retained Earnings	-587,460.00	-591,460.00
Net Income	-290.75	
Total Equity	$ 133,709.25	$ 130,000.00
TOTAL LIABILITIES AND EQUITY	$ 160,709.25	$ 146,000.00

The accompanying notes are an integral part of these fianancial statements.

MEDX HOLDINGS, INC
(A Development Stage Company)
Statement of Cash Flows
January - December 2015 & 2014

	Jan-Dec 2015	Jan-Dec 2014	Cumulative results from September 6 2006 (inception date) to December 31, 2015
OPERATING ACTIVITIES			
Net Loss	$ (291)	$ (570)	$ (587,751)
Adjustments to reconcile Net Income to Net Cash provided by operations:			
Accrued Liabilities	(16,000)		
Due to related party	27,000		27,000
Net cash provided by operating activities	**10,709**	**(570)**	**(560,751)**
INVESTING ACTIVITIES			
Capitalized Re-Organization Costs	(13,000)		(13,000)
Purchase of Capital Asset			(146,000)
Net cash provided by investing activities	**(13,000)**		**(159,000)**
FINANCING ACTIVITIES			
Common Stock	-		4,221
Paid-In Capital			717,239
Retained Earnings	4,000		
Net cash provided by financing activities	**4,000**		**721,460**
Net cash increase for period	1,709		1,709
Cash at end of period	$ 1,709		$ 1,709

The accompanying notes are an integral part of these financial statements.

MEDX HOLDINGS, INC.
(A Developing Stage Company)
Profit and Loss
January - December 2015 & 2014

	Jan - Dec 2015	Jan - Dec 2014 (PY)	Cumulative results from September 6, 2006 (Inception date) to December 31, 2015
Income			
Total Income			
Expenses			
Professional Fees	$ -		$ 24,500
Office/General Administrative Expenses	290.75	570.00	5241
Total Expenses	$ 290.75	$ 570.00	$ 587,751
Net Loss	-$ 290.75	-$ 570.00	$ (587,751)

STATEMENT OF STOCKHOLDERS' DEFICIT

BASIC LOSS PER COMMON SHARE	0.00	0.00
FULLY DILUTED LOSS PER COMMON SHARE	0.00	0.00
Weighted Average number of Common Shares Outstanding	25,569,016	42,217,852
Fully diluted weighted average number of Shares Outstanding	73,569,016	42,217,852

The accompanying notes are an integral part of these financial statements.

MEDX HOLDINGS, INC.

(A Development Stage Company)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

December 31, 2015

NOTE 1 - SUMMARY OF OPERATIONS AND BASIS OF PRESENTATION

Medx Holdings, Inc. formerly Cantor Group Inc. (the "Company") was re-domicile in the State of Wyoming on December 23, 2015. The company has an established fiscal year end of December 31.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Cash and Cash Equivalents

The company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Financial Instruments

The carrying value of the company's financial instruments approximates their fair value because of the short maturity of these instruments.

Basic and Diluted Net Loss per Share

The Company computes loss per share in accordance with "ASC-200". "Earnings per Share" which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Dilutive loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has issued four notes (DUE RELATED PARTIES) which are potential dilutive instruments an accordingly basic loss and diluted loss per share are presented. The Basic Common Stock authorized is 100,000,000 shares. As of

12/31/2015 the number of issued shares is 25,569,016 outstanding. The weighted average of fully diluted shares is 65,569,016.

NOTE 3 – GOING CONCERN

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has restructured its board and its management team and has raised equity capital to position the company as a holding company focused on acquisition and development of businesses primarily in the medical products industry. The Company is utilizing a new form of collaborative governance to create added value.

The ability of the Company to continue as a going concern is dependent upon its continued ability to successfully accomplish the plans descried in the preceding paragraph. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 4 - RELATED PARTY TRANSACTION

As of December 31, 2015 the Company owed $ 12,000.00 in a Convertible Note with four (4) individuals each owning ¼ each of the note via a partial Note Assignment. The notes remain non-interest bearing. The notes convert at $0.0001 up to 48,000,000 common Shares.

On November 17, 2015, Small Cap Pro LLC, funded a special purpose account on behalf of MEDX HOLDINGS, INC. in the amount of $ 15,000.00 with the sole purpose of providing working capital to re-structure the operations, move the state of domicile from Colorado to Wyoming, and to establish corporate operations in order to implement the current strategic business plan. This note carries a statutory interest rate, is unsecured and is due on demand. Small Cap Pro LLC is wholly owned by the principle shareholder of Medx Holdings, Inc.

NOTE 5 – PRIOR PERIOD ADJUSTMENT OF RETAINED EARNINGS

During the fourth (4th) quarter of 2015 management was informed that the owner of $ 4000.00 of accrued liability was relinquishing any claim on the Company for repayment. The Company therefore recognized the reduction in accrued liabilities with a corresponding increase in retained earnings of $ 4000.00

NOTE 6 – CAPITAL STOCK

As of December 31, 2015 the Company has:

Authorized Common Shares	100,000,000 Par Value $0.001
Authorized Blank Check Preferred	100,000,000 Par Value $0.001
Issued and outstanding:	25,569,016

NOTE 6 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were available to be issued and has determined that the significant change of ownership to Kathleen Roberton is important. Other than this change, it has been determined that there are no other significant events to disclose.

Item 6: Nature of the issuer's business

CATG was sold during the fiscal year of 2015 to Donald Schellpfeffer MD/PHD. David Black resigned as President, Secretary and Chief Executive Officer. Dr. Schellpfeffer was appointed as Chairman of the Board, President and Chief Executive Officer. On December 28, 2015 the Corporation was moved to Wyoming and a new name was chosen MedX Holdings. MedX is a developmental business. In 2013 the Corporation developed its current business strategy and has also been developing and further researching the strategy of Wearable Technology Heat. Prior management developed its Wearable Technology Heat Business Plan, which new management continues to manage and expand.

In addition to the core business of Wearable Technology Heat, new management plans to also focus on restructuring MedX into a Holding Company to acquire a variety of medical businesses that have our core philosophy within their own business model as a goal, i.e. Collaborative Profit™.

MedX will utilize a new form of Collaborative Governance, known as "Collaborative Profit™" to attract profitable businesses in the medical sector. MedX will focus on acquisitions of undervalued, niche companies with high growth potential, income-producing businesses including marketable securities. Our goal is to provide a new form of governance enabling businesses to take advantage of the power of a public company without losing management control.

The Company's fiscal year end is December 31st. The Company has not been involved in any bankruptcy, receivership, or any similar proceeding. The Company did undergo a reorganization of its share structure on September 9, 2015. The restructuring of the Company's Common Share structure involved a 250 to 1 reverse stock split with all fractional shareholders being rounded up to 1 whole share. The net effect of the restructuring was that the holder of the old shares underwent a 250 to 1 reverse split with no shareholder receiving less than 1 share of newly restructured Common Shares.

The Company dissolved the Corporation in Colorado and cancelled the 10,000,000 Preferred shares on December 29, 2015. The Company was domiciled with the original history and incorporation date in the state of Wyoming under the name MedX Holdings, Inc. on December 23, 2015.

MedX Holdings, Inc. was approved by FINRA to officially changed our name and symbol on February 18, 2016.

The Company is not currently subject to any legal action or in default of any debt covenants.

A. The Form of organization of the issuer:

MedX Holdings, Inc. is a Wyoming Corporation

B. The Year that the issuer (or any predecessor was organized):

The Company was incorporated on September 5, 2005 as Disaboo, Inc. under the laws of the state of Colorado.

Issuer's fiscal year end date:

Our fiscal year end is December 31st

Item 7: Describe the Issuer's Facilities:

Office Location:

1621 Central Avenue
Cheyenne, WY 82001

The Company is currently in a temporary office while seeking a permanent location in Jackson Hole, Wyoming. The Company does not rely on a retail office space as all executives can work remotely.

Item 8: Officers, Directors and Control Persons:

A. In November of 2015 David Black stepped down as CEO and President of the Company and Donald Schellpfeffer, MD/PHD was appointed CEO and President. David Black was removed from the Board and Dr. Schellpfeffer is the only Board member.

B. Legal/Disciplinary History:

None

C. Beneficial Owner:

Kathleen Roberton
1621 Central Avenue
Cheyenne Wyoming 82001

Percentage: Greater than 99%

Item 9: Third Party Providers

Legal Counsel:

Lorin A. Rosen, Esq.
Managing Attorney
Lar Law Firm
6 Butler Court
Centereach NY 11720
Accountant:

Irick CPA
Box 732
Counselor, NM 87018

Subsequent Events:

On January 14th 2016 Dr. Donald Schellpfeffer, MD/PHD sold the company to Kathleen Roberton. Dr. Schellpfeffer, MD/PHD resigned as Chairman, President, Secretary and CEO; Kathleen Roberton was appointed President, Secretary and CEO holding 99+% of the Issued and Outstanding Shares of the company.

Item 10: Issuer Certification

I Kathleen Roberton certify that:

1. I have reviewed this Annual Report;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the Issuer as of, and for, the period presented in this disclosure.

/s/ Kathleen Roberton, CEO

Kathleen Roberton, CEO